查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016360

短腸症候群市場：2026年至2032年全球市場預測（依治療方法、產品類型、給藥途徑、病患年齡、病因及應用分類）

Short Bowel Syndrome Market by Treatment Type, Product Type, Route Of Administration, Patient Age, Etiology, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，短腸症候群市場價值將達到 12.2 億美元，到 2026 年將成長至 13.2 億美元，複合年成長率為 9.50%，到 2032 年將達到 23.1 億美元。

主要市場統計數據
基準年 2025 12.2億美元
預計年份：2026年 13.2億美元
預測年份 2032 23.1億美元
複合年成長率 (%) 9.50%

簡明概述了重塑腸衰竭患者護理的多方面臨床、後勤和治療趨勢。

短腸症候群是一種複雜的多學科臨床挑戰，需要協調的護理模式、創新治療方法和高度靈活的供應鏈。患者腸道功能喪失程度不一，需要個別化的口服營養支持、腸外營養、藥物治療、在某些情況下進行手術介入。每條治療路徑都有其獨特的物流要求和臨床終點，而近期的進展已將重點從維持生命轉向恢復生活品質和減少對腸外營養的長期依賴。

治療方法創新、醫療服務分散化和供應鏈韌性如何全面重新定義短腸症候群。

由於治療方法的創新、醫療服務分散化以及監管要求的不斷變化，短腸症候群的現狀正在經歷一場變革。在治療方面，標靶藥物的出現正在重新定義治療目標，臨床醫生被鼓勵追求腸道康復，減少對腸外營養的依賴，而不是無限期地維持營養支持。外科手術技術也不斷進步，精細的腸道延長技術和更協調的移植途徑，共同拓寬了病患的選擇，同時也對傳統的治療方案提出了新的挑戰。

評估近期關稅措施對短腸症候群生態系中的供應穩定性、臨床連續性和商業策略的溢出效應。

對進口醫療用品和原料徵收新關稅，給整個短腸症候群醫療保健生態系統帶來了明顯壓力，影響到製造商、經銷商和醫療服務提供者。氨基酸混合物、脂肪乳劑和特殊經腸營養等關鍵成分的供應路線涉及複雜的全球網路。這些原料的關稅使採購變得更加複雜，迫使製造商重新評估籌資策略。為了因應這種情況，各機構正努力實現供應商多元化，增加庫存緩衝，並在可能的情況下轉向使用國內生產的原料，以降低國際貿易摩擦的風險。

對臨床、產品、給藥途徑、醫療保健環境、年齡和病因等細分領域進行全面分析，以確定短腸症候群的治療需求和市場定位。

對市場區隔的深入理解揭示了臨床需求、產品設計和護理環境如何相互交織，共同塑造競爭格​​局和臨床路徑。分析治療方法類型，其範圍涵蓋口服補充劑、腸外營養、藥物治療和外科手術。口服補充劑進一步細分為營養補充劑和營養製劑；腸外營養分為個體化配方和標準配方；藥物治療分為抗生素、生長因子和激素；外科手術包括腸移植和腸延長術。這種基於治療方法的細分突顯了不同的需求促進因素。有些患者依賴藥物來增強吸收，有些患者需要長期接受定製或標準化配方的腸外營養支持，還有一些患者則需要接受外科手術治療。

醫療保健基礎設施、報銷制度和醫療保健提供者能力方面的區域差異如何影響全球短腸症候群市場的准入和滲透率？

區域趨勢對全球短腸症候群領域的臨床實踐模式、監管預期和商業策略有顯著影響。在美洲，完善的家庭輸液基礎設施和成熟的報銷機制為先進的營養療法提供了支持，並促進了旨在恢復腸道功能的藥物的引入。該地區的相關人員強調將短腸症候群治療與慢性病管理模式結合，並加大對病患教育和遠端監測的投入，以減少病患對醫院的依賴，並改善長期治療效果。

深入了解策略聯盟、配方專業化和綜合護理能力如何決定短腸症候群的競爭優勢。

短腸症候群領域的競爭動態呈現出多元化的特徵，既有大型製藥和營養公司，也有專注於生物製藥研發的企業，以及提供複雜液體輸注和居家照護服務供應商。主要企業致力於透過專有配方、臨床醫生培訓計畫以及對供應鏈的投資來實現顯著差異化，以確保關鍵腸外和經腸營養產品的品質穩定性。同時，一些高度專業化的創新企業則專注於開發針對腸道適應的標靶療法，並透過與臨床中心合作，提供能夠帶來變革性臨床實踐的證據，從而尋求自身在特定領域的競爭優勢。

製造商、醫療保健提供者和支付方應實施的可操作的策略和營運重點，以確保患者獲得治療並加快治療效果。

產業領導企業應將短期營運改善與長期策略投資相結合，以鞏固自身地位並改善患者療效。首先，他們必須優先考慮供應鏈多元化和關鍵原料（例如胺基酸、脂肪乳劑和特殊經腸營養成分）的雙重採購，從而降低關稅和貿易風險，同時確保臨床供應不間斷。同時，他們應投資於完善的居家照護護理支援項目，包括標準化培訓課程、遠端監測技術和藥劑師主導的藥物管理，以提高患者從住院治療過渡到居家照護時的安全性和用藥依從性。

臨床和商業性見解透過嚴格的、多方面的調查方法檢驗，該方法結合了臨床醫生的參與、文獻整合和營運審查。

本調查方法採用多模態方法，將初步質性研究結果與嚴謹的二次分析結合，以建構對短腸症候群現況的全面認知。初步調查方法包括對胃腸病學、外科、營養學和家庭輸液服務領域的臨床醫生進行詳細訪談，以及與供應鏈管理人員和保險公司代表進行結構化討論，以了解營運限制和報銷決定因素。除上述對話外，還與關鍵意見領袖（KOL）舉行了諮詢小組會議，以檢驗臨床路徑並確定不同患者群體中尚未滿足的需求。

將臨床創新、營運韌性和夥伴關係關係為中心的策略進行策略整合，這將決定未來的療效和可近性。

短腸症候群既帶來了持續的挑戰，也帶來了新的機遇，需要臨床醫生、製藥公司、保險公司和服務提供者通力合作。藥物和外科技術的進步拓展了治療選擇，而居家營養管理模式的轉變則要求加強物流、病患教育和遠端監測。貿易政策的變化和供應鏈中斷進一步加劇了這一局面，迫使各機構優先考慮具有韌性和適應性的籌資策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章短腸症候群市場（治療方法）

  • 口服補充劑
    • 營養補充品
    • 營養製劑
  • 腸外營養
    • 個體化靜脈營養
    • 標準靜脈營養
  • 藥物治療
    • 抗生素
    • 生長因子
    • 荷爾蒙藥物
  • 手術介入
    • 腸移植
    • 腸道延長

第9章：短腸症候群市場：依產品類型分類

  • 輔助性治療
    • 益生菌
    • 維生素和礦物質
  • 經腸營養
    • 基本營養素
    • 聚合物配方
    • 半元素營養補充品
  • 藥理製劑
    • 泰德古爾奇德
  • PN製劑
    • 胺基酸製劑
    • 碳水化合物製劑
    • 脂質乳劑

第10章短腸症候群市場：依給藥途徑分類

  • 靜脈
  • 口服

第11章 依患者年齡分類的短腸症候群市場

  • 成人版
  • 老年人
  • 兒童

第12章短腸症候群市場依病因分類

  • 先天性疾病
  • 克隆氏症
  • 腸繫膜缺血

第13章短腸症候群市場：依最終用途分類

  • 居家護理設施
  • 醫院
  • 專科診所

第14章短腸症候群市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章短腸症候群市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章短腸症候群市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國短腸症候群市場

第18章 中國短腸症候群市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ajinomoto Co., Inc.
  • Becton, Dickinson and Company
  • CordenPharma International AG
  • Gland Pharma Limited
  • Hikma Pharmaceuticals PLC
  • ICU Medical, Inc.
  • Lonza Group AG
  • Otsuka Holdings Co., Ltd.
  • Smiths Medical（Smiths Group plc）
  • Terumo Corporation
Product Code: MRR-0309FBC51139

The Short Bowel Syndrome Market was valued at USD 1.22 billion in 2025 and is projected to grow to USD 1.32 billion in 2026, with a CAGR of 9.50%, reaching USD 2.31 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.22 billion
Estimated Year [2026] USD 1.32 billion
Forecast Year [2032] USD 2.31 billion
CAGR (%) 9.50%

A concise overview of the multifaceted clinical, logistical, and therapeutic dynamics reshaping care for patients with intestinal failure

Short bowel syndrome represents a complex, multidisciplinary clinical challenge that demands coordinated care models, innovative therapeutics, and adaptive supply chains. Patients experience variable intestinal function losses that necessitate individualized combinations of oral supplementation, parenteral nutrition, pharmacological therapy, and sometimes surgical intervention. Each therapeutic pathway carries distinct logistical requirements and clinical endpoints, and recent advances have shifted the emphasis from merely sustaining life to restoring quality of life and reducing long-term dependence on parenteral support.

As care moves increasingly into community and home settings, clinical teams, payers, and manufacturers must reconcile the tension between specialized hospital-based interventions and scalable outpatient solutions. This dynamic elevates the importance of integrated care plans that connect nutritional management, pharmacologic optimization, and surgical decision-making. Moreover, innovations in biological agents and device-assisted procedures are altering the clinical conversation, prompting health systems to reassess clinical protocols, training needs, and infrastructure investments. Consequently, stakeholders must navigate a landscape where therapeutic efficacy, delivery logistics, and patient-centered outcomes intersect in novel ways.

How innovation in therapeutics, decentralization of care delivery, and supply chain resilience are collectively redefining short bowel syndrome management

The short bowel syndrome landscape is undergoing transformative shifts driven by therapeutic innovation, decentralization of care, and evolving regulatory expectations. On the therapeutic front, the emergence of targeted pharmacologic agents has redefined treatment goals, encouraging clinicians to pursue intestinal rehabilitation and reduction of parenteral dependence rather than indefinite support. Surgical innovation continues to progress with refined intestinal lengthening techniques and more coordinated transplant pathways, which collectively expand patient options and challenge traditional care algorithms.

Simultaneously, the migration of long-term nutritional management into the home and outpatient settings has intensified focus on reliable supply chains, patient training, and remote monitoring capabilities. Telehealth-enabled clinical follow-up and digital adherence tools are becoming integral to care plans, enabling earlier interventions and more efficient resource utilization. From a market perspective, manufacturers and service providers are responding with differentiated product portfolios that combine nutritional formulations, adjunctive therapies, and device-enabled support, while payers increasingly demand evidence of real-world outcomes and cost-effectiveness. As a result, competitive advantage now hinges on cross-functional orchestration that aligns clinical benefit with scalable delivery models and robust support services.

Evaluating the ripple effects of recent tariff actions on supply security, clinical continuity, and commercial strategies within the short bowel syndrome ecosystem

The imposition of new tariffs on imported medical goods and raw materials has created palpable stress across the short bowel syndrome care ecosystem, affecting manufacturers, distributors, and providers. Supply lines for critical components such as amino acid blends, lipid emulsions, and specialized enteral formulas traverse complex global networks; tariffs on these inputs increase procurement complexity and compel manufacturers to reassess sourcing strategies. In response, organizations are diversifying supplier bases, increasing inventory buffers, and, where feasible, shifting toward domestically produced inputs to reduce exposure to international trade friction.

These adjustments, however, carry downstream effects. Hospitals and home infusion providers must reconcile procurement variability with the clinical necessity for consistent product availability, prompting closer collaboration with suppliers and heightened scrutiny of contingency planning. Clinicians may observe greater variability in product substitution and formulation availability, requiring careful management to preserve clinical continuity. Moreover, tariffs influence the economics of clinical trials and commercial launches by raising the direct cost of imported investigational materials and device components, which can slow sponsor decision-making and extend timelines for market entry.

In aggregate, the tariff environment accelerates strategic realignment across the value chain: manufacturers prioritize supply chain resilience and cost-efficiency, service providers invest in logistics capabilities and supplier partnerships, and clinical networks emphasize therapeutic continuity under constrained procurement conditions. These shifts underscore the importance of proactive trade-risk management and collaborative contracting frameworks to safeguard patient access and maintain therapeutic consistency.

A comprehensive dissection of clinical, product, route, setting, age, and etiology segments that determines therapeutic needs and commercial positioning for short bowel syndrome

A nuanced understanding of segmentation reveals how clinical need, product design, and care settings intersect to shape competition and clinical pathways. When analyzing treatment type, the landscape spans oral supplementation, parenteral nutrition, pharmacological therapy, and surgical intervention, where oral supplementation subdivides into dietary supplements and nutritional formulas, parenteral nutrition distinguishes customized and standard formulations, pharmacological therapy separates into antibiotics, growth factors, and hormonal agents, and surgical intervention includes bowel transplantation and intestinal lengthening procedures. This treatment-based segmentation highlights distinct demand drivers: some patients rely on pharmacologic agents to enhance absorptive capacity, others require long-term parenteral support with either bespoke or standardized solutions, and a subset proceed to surgical restoration efforts.

Looking through the lens of product type, the market encompasses adjunctive therapies, enteral formulas, pharmacologics, and parenteral nutrition solutions. Adjunctive therapies further include probiotics and vitamins and minerals, while enteral formulas are differentiated into elemental, polymeric, and semi-elemental variants; pharmacologics center on agents such as teduglutide, and parenteral solutions cover amino acid solutions, carbohydrate solutions, and lipid emulsions. This product-focused map clarifies where clinical differentiation, formulation science, and regulatory pathways converge, signaling opportunities for formulation optimization and supportive therapy bundling.

Route of administration provides another critical axis, with intravenous and oral pathways dictating device needs, patient education requirements, and monitoring intensity. End-use segmentation across home care facilities, hospitals, and specialty clinics underscores the operational implications of each treatment pathway: home care emphasizes training, remote monitoring, and logistics; hospitals prioritize acute management and complex surgical interventions; specialty clinics focus on multidisciplinary rehabilitation and longitudinal follow-up. Patient age stratification into adult, geriatric, and pediatric cohorts reveals differing physiologic needs, dosing considerations, and caregiver dynamics, while etiology-based segments-congenital conditions, Crohn disease, and mesenteric ischemia-demonstrate heterogeneity in disease trajectory and therapeutic intent. Together, these intersecting segmentation frameworks inform product design, clinical trial populations, reimbursement strategies, and channel development, enabling stakeholders to align portfolio strategies with precise clinical and operational requirements.

How distinct regional healthcare infrastructures, reimbursement environments, and provider capabilities shape access and adoption across global short bowel syndrome markets

Regional dynamics exert a powerful influence on clinical practice patterns, regulatory expectations, and commercial strategies across the global short bowel syndrome landscape. In the Americas, established home infusion infrastructures and mature reimbursement pathways support advanced nutritional therapies and facilitate adoption of pharmacologic agents aimed at intestinal rehabilitation. Stakeholders in this region emphasize integration with chronic care models and investment in patient education and remote monitoring to reduce hospital reliance and improve long-term outcomes.

Across Europe, the Middle East & Africa, health systems exhibit varied levels of access to advanced therapeutics and specialized surgical services, necessitating differentiated market approaches. In several markets within this region, centralized hospital care remains the dominant model for complex interventions, while growing interest in outpatient nutritional management presents opportunities for localized manufacturing and tailored distribution partnerships. Policy heterogeneity and regulatory divergence require nuanced market access strategies that accommodate national reimbursement frameworks and clinical guidelines.

The Asia-Pacific region combines rapidly developing healthcare infrastructure with high population heterogeneity, creating both challenges and opportunities. Urban centers in this region increasingly adopt advanced pharmacologic and surgical solutions, while resource-constrained settings prioritize scalable enteral and parenteral strategies. For manufacturers and service providers, success depends on flexible product portfolios, collaborative partnerships with local distributors, and investments in clinician education to bridge gaps in care delivery and expand appropriate access across diverse healthcare systems.

Insights into how strategic partnerships, formulation specialization, and integrated care capabilities determine competitive advantage in short bowel syndrome

Competitive dynamics in the short bowel syndrome domain reflect a blend of large pharmaceutical and nutrition firms, specialty biologic developers, and service providers that manage complex infusion and home care delivery. Leading companies concentrate on charting clear differentiation through proprietary formulations, clinician-focused education programs, and supply chain investments that ensure consistency of critical parenteral and enteral products. At the same time, specialized innovators pursue niche advantages by developing targeted pharmacologics that address intestinal adaptation and by partnering with clinical centers to generate practice-changing evidence.

Strategic partnerships have become a common pathway to accelerate market entry and scale; collaborations between formulation experts and logistics specialists help bridge gaps between product innovation and reliable in-field delivery. Additionally, a growing number of companies are investing in digital care platforms that complement core products, enabling remote patient monitoring, adherence tracking, and streamlined infusion management. This convergence of product, service, and digital tools fosters a competitive environment where integrated solutions that reduce caregiver burden and demonstrably improve patient outcomes command attention from payers and providers alike. To remain relevant, companies must balance investments in R&D with pragmatic attention to manufacturing resilience, regulatory navigation, and value communication to diverse stakeholders.

Actionable strategic and operational priorities that manufacturers, providers, and payers should implement to safeguard access and accelerate therapeutic impact for patients

Industry leaders should pursue a mix of immediate operational improvements and longer-term strategic investments to strengthen position and enhance patient outcomes. First, prioritize supply chain diversification and dual sourcing for critical inputs such as amino acids, lipid emulsions, and specialized enteral components to reduce tariff and trade exposure and to support uninterrupted clinical delivery. Concurrently, invest in robust home care enablement programs that include standardized training curricula, remote monitoring technologies, and pharmacist-led medication management to improve safety and adherence as care shifts away from inpatient settings.

Second, align R&D focus with clinical endpoints that resonate with payers and providers by generating evidence on reduced parenteral dependence, hospital readmissions, and patient-reported quality of life. Where possible, pursue pragmatic studies and real-world evidence initiatives that demonstrate the effectiveness of combined therapeutic approaches across different patient etiologies and age groups. Third, cultivate partnerships with specialty clinics and multidisciplinary centers to streamline pathways for patients who may benefit from surgical options, growth factors, or intestinal rehabilitation services, ensuring that referral networks and care coordination mechanisms are optimized.

Lastly, develop flexible commercial models that accommodate regional reimbursement realities and support bundled contracting for integrated service-product offerings. By combining operational resilience, evidence-driven development, clinical partnerships, and adaptable go-to-market approaches, leaders can sustain competitive advantage while delivering more predictable and improved patient journeys.

A rigorous multimethod research approach combining clinician engagement, literature synthesis, and operational review to validate clinical and commercial insights

The research methodology employed a multimodal approach that synthesizes primary qualitative insight with rigorous secondary analysis to develop a holistic view of the short bowel syndrome landscape. Primary methods included in-depth interviews with clinicians across gastroenterology, surgery, nutrition, and home infusion services, as well as structured consultations with supply chain managers and payer representatives to understand operational constraints and reimbursement drivers. These conversations were complemented by advisory-panel sessions with key opinion leaders to validate clinical pathways and identify unmet needs across different patient cohorts.

Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, clinical trial registries, and public health guidance to map therapeutic mechanisms, safety profiles, and standard-of-care practices. Additionally, product labeling, manufacturing guidance documents, and distribution channel analyses informed assessments of formulation complexity and logistical requirements. Data quality procedures included triangulation across multiple sources, consistency checks against clinical guidelines, and iterative validation with clinical experts to ensure that conclusions reflect current practice and operational realities. Throughout the process, care was taken to disaggregate insights across treatment types, product classes, routes of administration, care settings, patient ages, and etiologies to preserve analytical granularity and practical relevance.

A strategic synthesis of clinical innovation, operational resilience, and partnership-focused strategies that will determine future efficacy and access

Short bowel syndrome presents both persistent challenges and emerging opportunities that require coordinated responses from clinicians, manufacturers, payers, and service providers. Advances in pharmacologic agents and surgical techniques expand therapeutic possibilities, while the shift toward home-based nutritional management demands strengthened logistics, patient education, and remote monitoring. Trade policy changes and supply chain disruptions further complicate the environment, prompting organizations to prioritize resilience and adaptable sourcing strategies.

Moving forward, sustainable progress will depend on the ability to integrate evidence generation with practical delivery models that prioritize patient-centered outcomes. Stakeholders that align clinical innovation with operational excellence, cultivate partnerships across the care continuum, and communicate clear value propositions to payers will be best positioned to improve patient trajectories and create durable commercial advantage. In this context, actionable intelligence that bridges clinical nuance and real-world delivery mechanics becomes an essential input for strategic decision-making and effective program execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Short Bowel Syndrome Market, by Treatment Type

  • 8.1. Oral Supplementation
    • 8.1.1. Dietary Supplements
    • 8.1.2. Nutritional Formulas
  • 8.2. Parenteral Nutrition
    • 8.2.1. Customized Pn
    • 8.2.2. Standard Pn
  • 8.3. Pharmacological Therapy
    • 8.3.1. Antibiotics
    • 8.3.2. Growth Factors
    • 8.3.3. Hormonal Agents
  • 8.4. Surgical Intervention
    • 8.4.1. Bowel Transplantation
    • 8.4.2. Intestinal Lengthening Procedures

9. Short Bowel Syndrome Market, by Product Type

  • 9.1. Adjunctive Therapies
    • 9.1.1. Probiotics
    • 9.1.2. Vitamins And Minerals
  • 9.2. Enteral Formulas
    • 9.2.1. Elemental Formulas
    • 9.2.2. Polymeric Formulas
    • 9.2.3. Semi-elemental Formulas
  • 9.3. Pharmacologics
    • 9.3.1. Teduglutide
  • 9.4. Pn Solutions
    • 9.4.1. Amino Acid Solutions
    • 9.4.2. Carbohydrate Solutions
    • 9.4.3. Lipid Emulsions

10. Short Bowel Syndrome Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Short Bowel Syndrome Market, by Patient Age

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Short Bowel Syndrome Market, by Etiology

  • 12.1. Congenital Conditions
  • 12.2. Crohn Disease
  • 12.3. Mesenteric Ischemia

13. Short Bowel Syndrome Market, by End Use

  • 13.1. Home Care Facilities
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Short Bowel Syndrome Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Short Bowel Syndrome Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Short Bowel Syndrome Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Short Bowel Syndrome Market

18. China Short Bowel Syndrome Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Ajinomoto Co., Inc.
  • 19.6. Becton, Dickinson and Company
  • 19.7. CordenPharma International AG
  • 19.8. Gland Pharma Limited
  • 19.9. Hikma Pharmaceuticals PLC
  • 19.10. ICU Medical, Inc.
  • 19.11. Lonza Group AG
  • 19.12. Otsuka Holdings Co., Ltd.
  • 19.13. Smiths Medical (Smiths Group plc)
  • 19.14. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CUSTOMIZED PN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY STANDARD PN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HORMONAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY BOWEL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTESTINAL LENGTHENING PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY VITAMINS AND MINERALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ELEMENTAL FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY POLYMERIC FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SEMI-ELEMENTAL FORMULAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TEDUGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY AMINO ACID SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CARBOHYDRATE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY LIPID EMULSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CONGENITAL CONDITIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY CROHN DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY MESENTERIC ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOME CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 264. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 267. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 268. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 270. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 272. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 273. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 275. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 277. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 309. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY ORAL SUPPLEMENTATION, 2018-2032 (USD MILLION)
  • TABLE 312. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 313. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 314. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 315. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY ADJUNCTIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 317. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY ENTERAL FORMULAS, 2018-2032 (USD MILLION)
  • TABLE 318. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 319. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY PN SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 320. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. G7 SHORT BOWEL SYNDROME MA